IDYA
Price
$27.16
Change
+$1.33 (+5.15%)
Updated
Sep 5 closing price
Capitalization
2.38B
66 days until earnings call
NERV
Price
$2.35
Change
+$0.04 (+1.73%)
Updated
Sep 5 closing price
Capitalization
16.43M
65 days until earnings call
Interact to see
Advertisement

IDYA vs NERV

Header iconIDYA vs NERV Comparison
Open Charts IDYA vs NERVBanner chart's image
IDEAYA Biosciences
Price$27.16
Change+$1.33 (+5.15%)
Volume$1.65M
Capitalization2.38B
Minerva Neurosciences
Price$2.35
Change+$0.04 (+1.73%)
Volume$3.36K
Capitalization16.43M
IDYA vs NERV Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. NERV commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and NERV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (IDYA: $27.16 vs. NERV: $2.35)
Brand notoriety: IDYA and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 163% vs. NERV: 12%
Market capitalization -- IDYA: $2.38B vs. NERV: $16.43M
IDYA [@Biotechnology] is valued at $2.38B. NERV’s [@Biotechnology] market capitalization is $16.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 5 TA indicator(s) are bullish while NERV’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 5 bullish, 4 bearish.
  • NERV’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than NERV.

Price Growth

IDYA (@Biotechnology) experienced а +10.63% price change this week, while NERV (@Biotechnology) price change was -0.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

NERV is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.38B) has a higher market cap than NERV($16.4M). NERV (5.780) and IDYA (5.681) have similar YTD gains . NERV has higher annual earnings (EBITDA): 11.2M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. NERV (15.2M). NERV has less debt than IDYA: NERV (0) vs IDYA (26.6M). IDYA has higher revenues than NERV: IDYA (7M) vs NERV (0).
IDYANERVIDYA / NERV
Capitalization2.38B16.4M14,512%
EBITDA-380.2M11.2M-3,395%
Gain YTD5.6815.78098%
P/E RatioN/A1.56-
Revenue7M0-
Total Cash670M15.2M4,408%
Total Debt26.6M0-
FUNDAMENTALS RATINGS
IDYA vs NERV: Fundamental Ratings
IDYA
NERV
OUTLOOK RATING
1..100
2028
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
34
Fair valued
PROFIT vs RISK RATING
1..100
68100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4741
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5043

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (34) in the Biotechnology industry is in the same range as IDYA (63) in the null industry. This means that NERV’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (68) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to NERV’s over the last 12 months.

IDYA's SMR Rating (96) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to NERV’s over the last 12 months.

NERV's Price Growth Rating (41) in the Biotechnology industry is in the same range as IDYA (47) in the null industry. This means that NERV’s stock grew similarly to IDYA’s over the last 12 months.

NERV's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that NERV’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYANERV
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 10 days ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
77%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TFESX12.84N/A
N/A
Templeton Instl Intl Eq Ser Service
PCEQX24.67N/A
N/A
Victory Pioneer Equity Income C
MGOTX8.86N/A
N/A
Victory Munder Mid-Cap Core Growth C
SCMIX175.99N/A
N/A
Columbia Seligman Tech & Info Inst2
MMUJX24.22N/A
N/A
MFS Utilities R4

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with DNLI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
+1.73%
DNLI - NERV
34%
Loosely correlated
+4.33%
ANAB - NERV
33%
Poorly correlated
+3.84%
IDYA - NERV
32%
Poorly correlated
+5.15%
MLTX - NERV
31%
Poorly correlated
-0.47%
GBIO - NERV
31%
Poorly correlated
+3.63%
More